Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study.

The difference between the vitamin E 300 mg treatment and the placebo groups in fibrosis improvement by at least one stage without worsening of steatohepatitis after 96 weeks (the exploratory secondary endpoint) did not reach statistical significance (25.9% vs. 15.6%, respectively; OR, 1.9; 95% CI: 0.7–5.2; p = 0.16) ( Figure 2 B).

also in 111,027 other papers